Medicine put to the test

As an independent scientific institute, IQWiG examines the benefits and harms of medical interventions for patients. We provide information about the advantages and disadvantages of examination and treatment methods in the form of scientific reports and easily understandable health information.

Latest news

Press Releases

Press Releases

Atezolizumab, pembrolizumab, nivolumab in urothelial carcinoma: Studies of direct comparison are useful

2018-01-04 Four dossier assessments in 2017 involving comparisons between immunotherapies and chemotherapies for the same indication. Yet, a comparison of immunotherapies among each other is missing.

read more Link to \Atezolizumab, pembrolizumab, nivolumab in urothelial carcinoma: Studies of direct comparison are useful\""

Atezolizumab, pembrolizumab, nivolumab in urothelial carcinoma: Studies of direct comparison are useful

2018-01-04 Four dossier assessments in 2017 involving comparisons between immunotherapies and chemotherapies for the same indication. Yet, a comparison of immunotherapies among each other is missing.

read more Link to \Atezolizumab, pembrolizumab, nivolumab in urothelial carcinoma: Studies of direct comparison are useful\""

Biomarker tests in early breast cancer: IQWiG criticizes interpretation of MINDACT data in an updated US guideline

2017-12-20 In their updated guideline, US oncologists recently recommended the MammaPrint test. Researchers from IQWiG have reacted in a letter to the editor in the Journal of Clinical Oncology.

read more Link to \Biomarker tests in early breast cancer: IQWiG criticizes interpretation of MINDACT data in an updated US guideline\""

Tenofovir alafenamide in chronic hepatitis B: added benefit not proven, data incomplete

2017-07-03 No added benefit can be derived from the incompletely submitted data for adolescents or adults. The postulated better tolerability is not proven.

read more Link to \Tenofovir alafenamide in chronic hepatitis B: added benefit not proven, data incomplete\""

Secukinumab and ixekizumab in psoriasis: considerable added benefit for certain patients

2017-06-01 There were notably more remissions than under the comparator therapies. In future, the analysis of symptoms should not be limited to improvements at one time point.

read more Link to \Secukinumab and ixekizumab in psoriasis: considerable added benefit for certain patients\""

Pembrolizumab in non-small cell lung cancer: hint of considerable added benefit

2017-05-15 Good study design allows identification of the relevant subpopulation, in which prolonged overall survival notably outweighs disadvantages in some side effects.

read more Link to \Pembrolizumab in non-small cell lung cancer: hint of considerable added benefit\""

High-risk medical devices: IQWiG sees no potential in 6 of 8 cases

2017-03-17 Only case series without informative value are available for most indications. A plausible mode of action is insufficient to attribute a potential.

read more Link to \High-risk medical devices: IQWiG sees no potential in 6 of 8 cases\""

Tonsillotomy: fewer adverse effects in the short term, but renewed inflammation and surgery possible

2017-03-03 In the short term, tonsillotomy is associated with less pain, as well as fewer swallowing and sleeping problems, than tonsillectomy. But regrowing tissue can lead to renewed inflammation.

read more Link to \Tonsillotomy: fewer adverse effects in the short term, but renewed inflammation and surgery possible\""

Palbociclib in advanced breast cancer: Disadvantages predominate in certain patients

2017-03-01 More severe side effects occur under the combination of palbociclib and letrozole in the first-line treatment of postmenopausal women. Data were lacking for other patient groups.

read more Link to \Palbociclib in advanced breast cancer: Disadvantages predominate in certain patients\""

Measurement of fractional flow reserve offers advantages for certain patients with CHD

2017-01-09 Patients in whom the widening of blood vessels by means of percutaneous coronary intervention is planned benefit from the new diagnostic procedure; this is not the case for stable CHD.

read more Link to \Measurement of fractional flow reserve offers advantages for certain patients with CHD\""

Current commenting procedures (Hearings)

Current commenting procedures (Hearings)

No. Title Type Deadline
S16-06 Non-invasive prenatal testing to determine the risk of autosomal trisomies 13, 18 and 21 in high-risk pregnancies on the preliminary report 2018-01-24
N16-03 Motor-driven continuous passive motion (CPM) devices after interventions on the knee and shoulder joint on the preliminary report 2018-01-30

Calls for tenders advertised

Calls for tenders advertised

In general, calls for tenders are published in German. Interested parties can check current calls for tenders on the German website.


Easily understandable information for patients and the general community

Brodalumab (EU: Kyntheum, U.S.: Siliq) for psoriasis

Brodalumab (trade name EU: Kyntheum, U.S.: Siliq) has been approved in Germany since July 2017 for the systemic treatment of moderate to severe plaque psoriasis in adults.   read more (Link to \Brodalumab (EU: Kyntheum, U.S.: Siliq) for psoriasis\"" ‚Äì opens in a new window)


Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close